Does the media prefer CAI or GH?

In the previous week, Guardant Health had 3 more articles in the media than Caris Life Sciences. MarketBeat recorded 6 mentions for Guardant Health and 3 mentions for Caris Life Sciences. Guardant Health's average media sentiment score of 0.52 beat Caris Life Sciences' score of 0.38 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Guardant Health 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer BTSG or CAI?

In the previous week, BrightSpring Health Services and BrightSpring Health Services both had 3 articles in the media. BrightSpring Health Services' average media sentiment score of 1.35 beat Caris Life Sciences' score of 0.38 indicating that BrightSpring Health Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BrightSpring Health Services 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CAI or HIMS?

In the previous week, Hims & Hers Health had 19 more articles in the media than Caris Life Sciences. MarketBeat recorded 22 mentions for Hims & Hers Health and 3 mentions for Caris Life Sciences. Hims & Hers Health's average media sentiment score of 0.81 beat Caris Life Sciences' score of 0.38 indicating that Hims & Hers Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hims & Hers Health 12 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PACS or CAI?

In the previous week, PACS Group had 6 more articles in the media than Caris Life Sciences. MarketBeat recorded 9 mentions for PACS Group and 3 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.38 beat PACS Group's score of -0.33 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caris Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Caris Life Sciences (CAI) Competitors

$17.60 +0.29 (+1.68%)

As of 04:00 PM Eastern

Compare

CAI vs. GH, BTSG, FMS, HIMS, and PACS

Should you buy Caris Life Sciences stock or one of its competitors? MarketBeat compares Caris Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Caris Life Sciences include Guardant Health (GH), BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), Hims & Hers Health (HIMS), and PACS Group (PACS). These companies are all part of the "healthcare" industry.

How does Caris Life Sciences compare to Guardant Health?

Caris Life Sciences (NASDAQ:CAI) and Guardant Health (NASDAQ:GH) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Caris Life Sciences presently has a consensus target price of $27.56, suggesting a potential upside of 56.57%. Guardant Health has a consensus target price of $141.95, suggesting a potential upside of 8.50%. Given Caris Life Sciences' higher probable upside, equities research analysts clearly believe Caris Life Sciences is more favorable than Guardant Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Caris Life Sciences has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$348.89M	14.26	-$68.09M	-$7.61	N/A
Guardant Health	$1.08B	16.06	-$416.28M	-$3.39	N/A

Caris Life Sciences has a net margin of 3.75% compared to Guardant Health's net margin of -40.10%. Caris Life Sciences' return on equity of 98.28% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Guardant Health	-40.10%	N/A	-26.42%

In the previous week, Guardant Health had 3 more articles in the media than Caris Life Sciences. MarketBeat recorded 6 mentions for Guardant Health and 3 mentions for Caris Life Sciences. Guardant Health's average media sentiment score of 0.52 beat Caris Life Sciences' score of 0.38 indicating that Guardant Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Guardant Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

92.6% of Guardant Health shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by insiders. Comparatively, 5.6% of Guardant Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Guardant Health beats Caris Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Caris Life Sciences has a net margin of 3.75% compared to BrightSpring Health Services' net margin of 2.27%. Caris Life Sciences' return on equity of 98.28% beat BrightSpring Health Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.27%	14.63%	4.41%
Caris Life Sciences	3.75%	98.28%	48.87%

BrightSpring Health Services has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91B	1.02	$190.67M	$1.41	47.40
Caris Life Sciences	$348.89M	14.26	-$68.09M	-$7.61	N/A

In the previous week, BrightSpring Health Services and BrightSpring Health Services both had 3 articles in the media. BrightSpring Health Services' average media sentiment score of 1.35 beat Caris Life Sciences' score of 0.38 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrightSpring Health Services	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BrightSpring Health Services presently has a consensus target price of $61.27, suggesting a potential downside of 8.34%. Caris Life Sciences has a consensus target price of $27.56, suggesting a potential upside of 56.57%. Given Caris Life Sciences' higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than BrightSpring Health Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.11
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

BrightSpring Health Services beats Caris Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Fresenius Medical Care AG & Co. KGaA pays an annual dividend of $0.60 per share and has a dividend yield of 2.5%. Caris Life Sciences pays an annual dividend of $1.20 per share and has a dividend yield of 6.8%. Fresenius Medical Care AG & Co. KGaA pays out 31.6% of its earnings in the form of a dividend. Caris Life Sciences pays out -15.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Caris Life Sciences is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Caris Life Sciences had 2 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 3 mentions for Caris Life Sciences and 1 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 0.77 beat Caris Life Sciences' score of 0.38 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fresenius Medical Care AG & Co. KGaA	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.88% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%
Caris Life Sciences	3.75%	98.28%	48.87%

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of $28.00, suggesting a potential upside of 17.99%. Caris Life Sciences has a consensus target price of $27.56, suggesting a potential upside of 56.57%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Caris Life Sciences is more favorable than Fresenius Medical Care AG & Co. KGaA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius Medical Care AG & Co. KGaA	5 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.44
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA	$19.36B	0.66	$1.11B	$1.90	12.49
Caris Life Sciences	$348.89M	14.26	-$68.09M	-$7.61	N/A

Summary

Caris Life Sciences beats Fresenius Medical Care AG & Co. KGaA on 10 of the 17 factors compared between the two stocks.

How does Caris Life Sciences compare to Hims & Hers Health?

Caris Life Sciences (NASDAQ:CAI) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Hims & Hers Health had 19 more articles in the media than Caris Life Sciences. MarketBeat recorded 22 mentions for Hims & Hers Health and 3 mentions for Caris Life Sciences. Hims & Hers Health's average media sentiment score of 0.81 beat Caris Life Sciences' score of 0.38 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hims & Hers Health	12 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences presently has a consensus price target of $27.56, indicating a potential upside of 56.57%. Hims & Hers Health has a consensus price target of $29.37, indicating a potential downside of 11.01%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Caris Life Sciences is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Hims & Hers Health	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Caris Life Sciences has a net margin of 3.75% compared to Hims & Hers Health's net margin of -0.56%. Caris Life Sciences' return on equity of 98.28% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Hims & Hers Health	-0.56%	6.10%	1.52%

Hims & Hers Health has higher revenue and earnings than Caris Life Sciences. Hims & Hers Health is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$348.89M	14.26	-$68.09M	-$7.61	N/A
Hims & Hers Health	$2.35B	3.25	$128.37M	-$0.09	N/A

63.5% of Hims & Hers Health shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Caris Life Sciences beats Hims & Hers Health on 9 of the 15 factors compared between the two stocks.

How does Caris Life Sciences compare to PACS Group?

PACS Group (NYSE:PACS) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

In the previous week, PACS Group had 6 more articles in the media than Caris Life Sciences. MarketBeat recorded 9 mentions for PACS Group and 3 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.38 beat PACS Group's score of -0.33 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PACS Group currently has a consensus price target of $48.00, suggesting a potential upside of 28.72%. Caris Life Sciences has a consensus price target of $27.56, suggesting a potential upside of 56.57%. Given Caris Life Sciences' higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

PACS Group has a net margin of 4.49% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat PACS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Caris Life Sciences	3.75%	98.28%	48.87%

PACS Group has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	1.12	$191.54M	$1.56	23.90
Caris Life Sciences	$348.89M	14.26	-$68.09M	-$7.61	N/A

Summary

PACS Group beats Caris Life Sciences on 7 of the 13 factors compared between the two stocks.

Get Caris Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAI vs. The Competition

Export

Metric	Caris Life Sciences	Services – Health Industry	Services Sector	NASDAQ Exchange
Market Cap	$4.98B	$1.85B	$14.22B	$12.14B
Dividend Yield	N/A	N/A	5.01%	5.81%
P/E Ratio	-2.31	17.10	11.68	24.05
Price / Sales	14.26	21.26	42.88	102.06
Price / Cash	11.59	168.23	57.38	37.84
Price / Book	8.59	38.73	12.49	6.55
Net Income	-$68.09M	-$33.67M	-$12.25M	$336.99M
7 Day Performance	-2.11%	1.55%	1.07%	-0.10%
1 Month Performance	13.18%	6.44%	5.24%	0.90%
1 Year Performance	N/A	N/A	40.34%	31.76%

Caris Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAI Caris Life Sciences	4.4187 of 5 stars	$17.60 +1.7%	$27.56 +56.6%	N/A	$4.98B	$348.89M	N/A	1,846
GH Guardant Health	1.8235 of 5 stars	$131.62 +0.6%	$141.95 +7.9%	+162.2%	$17.45B	$982.02M	N/A	2,506
BTSG BrightSpring Health Services	4.1455 of 5 stars	$63.23 +0.2%	$58.53 -7.4%	+201.8%	$12.47B	$12.91B	44.84	23,500	Positive News Analyst Upgrade
FMS Fresenius Medical Care AG & Co. KGaA	4.2794 of 5 stars	$23.03 +3.0%	$28.00 +21.6%	-12.8%	$12.43B	$22.20B	12.12	1,488	News Coverage
HIMS Hims & Hers Health	3.107 of 5 stars	$26.85 -7.0%	$28.70 +6.9%	-47.9%	$6.21B	$2.35B	N/A	2,442	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAI) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caris Life Sciences (CAI) Competitors

CAI vs. GH, BTSG, FMS, HIMS, and PACS

How does Caris Life Sciences compare to Guardant Health?

Summary

How does Caris Life Sciences compare to BrightSpring Health Services?

Summary

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Summary

How does Caris Life Sciences compare to Hims & Hers Health?

Summary

How does Caris Life Sciences compare to PACS Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caris Life Sciences (CAI) Competitors

CAI vs. GH, BTSG, FMS, HIMS, and PACS

How does Caris Life Sciences compare to Guardant Health?

Do analysts prefer CAI or GH?

Which has higher valuation & earnings, CAI or GH?

Is CAI or GH more profitable?

Does the media prefer CAI or GH?

Do insiders and institutionals have more ownership in CAI or GH?

Summary

How does Caris Life Sciences compare to BrightSpring Health Services?

Is BTSG or CAI more profitable?

Which has preferable valuation & earnings, BTSG or CAI?

Does the media prefer BTSG or CAI?

Do analysts prefer BTSG or CAI?

Summary

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Is FMS or CAI a better dividend stock?

Does the media prefer FMS or CAI?

Do institutionals and insiders believe in FMS or CAI?

Is FMS or CAI more profitable?

Do analysts prefer FMS or CAI?

Which has stronger earnings & valuation, FMS or CAI?

Summary

How does Caris Life Sciences compare to Hims & Hers Health?

Does the media prefer CAI or HIMS?

Do analysts rate CAI or HIMS?

Is CAI or HIMS more profitable?

Which has preferable valuation and earnings, CAI or HIMS?

Do insiders and institutionals believe in CAI or HIMS?

Summary

How does Caris Life Sciences compare to PACS Group?

Does the media prefer PACS or CAI?

Do analysts prefer PACS or CAI?

Is PACS or CAI more profitable?

Which has stronger earnings and valuation, PACS or CAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools